Change in management
May 30, 2023
The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company.
Read moreMajor shareholder announcement
May 19, 2023
Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Scandinavian Investment Group A/S, that as of May 16, 2023, Scandinavian Investment Group A/S holds shares corresponding to 10.00% of the total share capital and voting rights in the Company.
Major shareholder announcement
Read moreMajor shareholder announcement
May 17, 2023
Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from MH Investment ApS, that as of May 16, 2023, MH Investment ApS holds shares corresponding to 10.00% of the total share capital and voting rights in the Company.
Major shareholder announcement
Read moreResolutions passed at the Annual General Meeting
May 17, 2023
Copenhagen, Denmark, May 17, 2023 – Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting.
Company announcement Resolutions passed at the Annual General Meeting
New members of the Board of Directors of Orphazyme
Read moreChanges to the Board of Directors
May 17, 2023
Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces that during the Annual General Meeting on May 17, 2023, Bo Jesper Hansen, John Sommer Schmidt and Anders Fink Vadsholt withdrew their candidacy as members of the Board of Directors.
Company announcement Change to Board of Directors
Read moreMajor shareholder announcement
May 12, 2023
Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Scandinavian Investment Group A/S that Scandinavian Investment Group A/S holds shares, corresponding to more than 5% of the total share capital and voting rights in the Company.
Major shareholder announcement
Read moreMajor shareholder announcement
May 9, 2023
Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from Nordic Compound Invest A/S that Nordic Compound Invest A/S holds shares, corresponding to more than 5% of the total share capital and voting rights in the Company.
Major shareholder announcement
Read moreMajor shareholder announcement
May 9, 2023
Orphazyme A/S (ORPHA.CO) (the “Company”), hereby announces the receipt of notification pursuant to Section 38 of the Danish Capital Markets Act from MH Investment ApS, that as of May 8, 2023, MH Investment ApS holds shares, corresponding to more than 5% of the total share capital and voting rights in the Company.
Major shareholder announcement
Read moreNotice to convene Annual General Meeting
Apr 25, 2023
Orphazyme A/S (ORPHA.CO) (the “Company”), today announces the notice to convene the Company’s Annual General Meeting to be held on: Wednesday, May 17, 2023 at 11:00 AM (CEST) at the offices of Gorrissen Federspiel, Axeltorv 2, DK-1609 Copenhagen V.
Appendix 1 Candidates for the Board of Directors
Announcement Notice to convene AGM 2023
Read moreOrphazyme Announces Publication of 2022 Financial Results and Annual Report
Apr 25, 2023
Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today announced its financial results for the period from January 1, 2022, to December 31, 2022, and publishes its Annual Report.
Announcement Annual Report 2022
Read more